Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

New Research Reveals Shocking Lack Of Dementia Awareness In UK
Research released by Alzheimer"s Society this Dementia Awareness Week has shown widespread misunderstanding about dementia and the factors that put people at risk.
generic viagra online
Massachusetts' Individual Mandates, Insurance Exchanges Are Examples For National Plan
"Three years into its experiment with near-universal health care, Massachusetts has some "dos and don"ts" for the nation as it grapples with the best way to cover tens of millions of uninsured Americans," the Associated Press reports. "Do require that virtually everyone have health insurance, the overriding goal in Massachusetts. Don"t ignore rising costs, the single greatest threat to the law"s long-term affordability."
News of the day
Additional "Unsuspected" Breast Cancers Not Seen On Mammography Or Ultrasound Detected By Breast MRI
A total of 199 patients with newly diagnosed breast cancer underwent breast MRI. "We found additional, unsuspected cancers in the ipsilateral breast (the one that had already been diagnosed with cancer) in 16% of patients; we found cancers in the contralateral breast (the one that had not been diagnosed with cancer) in 4% of patients," said Petra J. Lewis, MD, lead author of the study. "These patients had already had bilateral mammography and these tumors had not been apparent on mammography," said Dr. Lewis.
Public Health

Meda: Positive Study Supporting A Potential Once-Daily Nasal Antihistamine

In October 2008, the US Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for the newly formulated higher strength azelastine nasal spray as complete for substantive review after initial evaluation. This NDA contained data on six phase III studies and a long-term safety study, involving more than 1,600 patients in total. In these clinical studies, the product demonstrated improvement in nasal symptom relief scores in patients with seasonal and perennial allergic rhinitis, and was well tolerated. Parallel to FDA"s review process, Meda initiated a seventh phase III study. This study has now been completed and the results support a potential claim for a once-daily administration. Meda has decided to add this study to the submitted NDA. In response, FDA has requested three additional months to review this new information. Therefore, Meda anticipates a formal response on this NDA during September 2009. MEDA AB


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009